IMPEDIMED LIMITED — Board/Management Information 2017

Oct 15, 2017

16 October 2017

==> picture [226 x 42] intentionally omitted <==

ASX ANNOUNCEMENT

ImpediMed announces changes to Board of Directors

Brisbane, Australia, and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announces changes to its Board of Directors, to take effect immediately after the company’s Annual General Meeting which will be held on 15 November 2017.

Non-Executive Director Mr Scott Ward will be appointed to the role of Chair, replacing Dr Cherrell Hirst who is retiring from the Board after 12 years (including six as Chair). Professor Robert Graham, of the Victor Chang Cardiac Institute, will join the Board as one of the company’s Australian based non-executive directors.

Scott Ward joined the Board of ImpediMed in July 2013. He is currently the Chair of the Remuneration Committee and a member of the Nomination committee. Scott is also Chairman of the Board, President and CEO of Cardiovascular Systems Inc. and a Managing Director of SightLine Partners. He has over 35 years of experience in the healthcare industry, including 30 years at Medtronic Inc. where he served in various senior positions including the Senior Vice President and President of the Cardiovascular business.

Professor Robert (Bob) Graham is a leading molecular cardiologist, and Executive Director of the Victor Chang Cardiac Research Institute.

In addition to academic roles at the University of New South Wales and Case Western Reserve University School of Medicine, Cleveland, Ohio, Professor Graham is a Fellow of the Australian Academy of Science; the Australian Academy of Health & Medical Sciences; and foreign member of the Royal Danish Academy of Sciences and Letters. He is a member of the American Association for Clinical Research, the American Society of Clinical Investigation and the American Heart Association, and a Life Member of Heart Foundation of Australia.

“These Board changes complete the planned renewal and succession planning process that has been underway over recent years to ensure ImpediMed has the skills and leadership to guide it through its next phase of growth,” said Dr Cherrell Hirst, outgoing Chair of ImpediMed.

“I am very privileged to have served on this Board for the past 12 years, and to have worked with such a capable team of fellow Directors and executives. I know that I am leaving ImpediMed in a very strong position, given the significant strategic achievements of the past few years and the exceptional leadership skills of our Managing Director and CEO, Rick Carreon.”

.

For further information, contact:

Dr Cherrell Hirst, ImpediMed Chair T: +61 411 556 124

Media and Investor Contact:

In Australia:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[TM] , sold in select markets globally.

For more information, visit www.impedimed.com.